Subsequent Events (Details) - USD ($) $ in Millions |
1 Months Ended | 9 Months Ended | |
|---|---|---|---|
Oct. 31, 2019 |
Jan. 31, 2019 |
Sep. 30, 2019 |
|
| Subsequent Event [Line Items] | |||
| Approximate medicine approval decision term | 60 days | ||
| Grifols | |||
| Subsequent Event [Line Items] | |||
| Upfront payment received | $ 30.0 | $ 5.0 | |
| Grifols | fostamatinib | Upon EMA approval of fostamatinib for treatment of chronic ITP | |||
| Subsequent Event [Line Items] | |||
| Contingent payments | $ 20.0 | $ 20.0 | |
| Subsequent event | Medison Pharma | fostamatinib | |||
| Subsequent Event [Line Items] | |||
| Upfront payment received | $ 5.0 | ||
| X | ||||||||||
- Definition Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement. No definition available.
|
| X | ||||||||||
- Definition Represents additional contingent payments by entities. No definition available.
|
| X | ||||||||||
- Definition Period of time between opinion and medicine approval decision, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|